The PI3K/AKT pathway is another important pathway in RCC progression, and it is reported that exogenous H2S inhibits this pathway, and therefore, exogenous H2S could be a novel targeted therapy of RCC [135, 136]. This evidence concerns the gene AKT1 and renal cell carcinoma.